HIGHLIGHTS
- who: Bruce Spottiswoode and colleagues from the Healthcare GmbH, Erlangen, GermanyUniversity Hospitals have published the Article: Deep-Learning 18F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma, in the Journal: (JOURNAL)
- what: This trial is a phase III study that was designed to assess the efficacy of lenalidomide versus placebo in responding elderly DLBCL patients (60-80 y old) treated with the standard first-line rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate, and prednisone (R-CHOP) therapy approach . The authors evaluated a fully automated application of PARS.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.